A phase-2 human clinical study showed that patients with nonalcoholic fatty liver disease (NAFLD) experienced a significant reduct...
ScandiBio Therapeutics announced Phase 2 clinical trial results from the study “Combined Metabolic Activators Improve Cognitive...
ScandiBio Therapeutics announced Phase 2 clinical trial results from the study “Combined Metabolic Activators Improves Cognitive...
The results of a Phase II and III studies have been published in the journal Advanced Science. COVID-19 is associated with mi...
The Swedish biotechnology company ScandiBio Therapeutics today announced results from the study “Combined Metabolic Activators A...
ScandiBio Therapeutics announced results from the study “Combined Metabolic Activators Reduces Liver Fat in Nonalcoholic Fatty L...
ScandiBio Therapeutics has completed a Phase II study based on treatment of patients with COVID-19. Patients with mild-to-moderate...
A review paper has been published in the journal iScience about the use of drug repositioning applications in treatment of COVID-1...
A review paper has been published in the journal Frontiers in Neuroscience discussing the use of AI-based systems biology approach...
The Board of Directors of ScandiBio Therapeutics has, in accordance with the issue authorization granted by the extraordinary gene...